Clinical trial
A Randomised, Double-blind, Placebo-controlled Phase IIa Trial to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BI 3810477 With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis
NCT07926321 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo-controlled Phase IIa Trial to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BI 3810477 With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 13, 2026
- Completion date
- April 20, 2028
- Enrollment
- 70 (estimated)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Placebo
-
BI 3810477
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 12
Lead sponsor's other trials
Boehringer Ingelheim, most recent start first.
+2,298 more trials See the organization page
Similar trials
Same condition (Idiopathic Pulmonary Fibrosis) and phase, most recent start first.
+132 more trials See the condition page